Lifestyle Still Wins: The 2025 Case for Diet, Exercise and the Metabolic Trio
A major Herz review reaffirms that Mediterranean eating, structured movement and smoking cessation move the endpoints that matter — a useful corrective in the GLP-1 era.
For two years, the conversation about metabolic health has been dominated by a single class of molecules. GLP-1 medications have rewritten what patients, clinicians and insurers expect from weight loss, and the cultural gravity around them is hard to overstate. So it is worth pausing on a quieter signal from the research literature: a 2025 review in Herz that re-examines what diet, movement and smoking cessation still do for the people most at risk of diabetes, obesity and cardiovascular disease — and concludes, plainly, that they still do a great deal.
The review, by Seth and colleagues, is a synthesis rather than a new trial. Its authors comb through large cohort studies and clinical trials to ask a deceptively simple question: in an era of effective drugs, how much of the cardiometabolic burden can still be moved by the things humans do every day? Their answer is measured. Lifestyle and pharmacotherapy, they argue, have emerged together as the new pillars of preventive medicine — not as rivals, but as a combined strategy whose parts each pull weight.
That framing matters because the public conversation has drifted toward an implicit either/or. If a weekly injection can produce double-digit weight loss, why bother with the harder, slower work of changing what is on the plate or how the afternoon is spent? The review’s response is not a moral one. It is mechanistic. Diabetes, obesity and cardiovascular disease share a common biology of systemic inflammation, insulin resistance and neurohormonal activation, and those pathways respond to inputs that no drug fully replicates: the composition of the diet, the load placed on skeletal muscle, the presence or absence of cigarette smoke.
The trio that keeps showing up
Three interventions recur across the evidence the authors review. A Mediterranean or plant-forward eating pattern. Structured physical activity and exercise training. Smoking cessation, with a reduction in alcohol intake as a useful adjunct. None of these are novel. All of them, according to the review, have shown promise in mitigating the risks that drive cardiometabolic disease.
The word promise is doing real work in that sentence. This is a review, not a randomized trial, and the underlying evidence base is heterogeneous — cohort studies sit alongside intervention trials of varying size and duration. The editorial evidence rating for this piece is moderate for a reason: the direction of effect is consistent and biologically plausible, but the precise magnitude any individual reader can expect remains uncertain. What the literature supports is a confident statement about pattern, not a precise promise about outcome.
The Mediterranean pattern is less a diet than a default: plants, legumes, olive oil and fish in rotation, with refined carbohydrates and processed meats edged out rather than banned.
It also helps to be specific about what these interventions are not. A Mediterranean pattern is not a branded program; it is a default — plants, legumes, olive oil, fish, modest dairy, with refined carbohydrates and processed meats stepping back. Structured exercise is not a punishing gym habit; the review treats it as a category that includes both aerobic conditioning and resistance training, prescribed with the same seriousness as a medication. Smoking cessation is the single most leveraged change a current smoker can make for their cardiovascular future, and the review reiterates it without hedging.
Only a multifaceted, sustained approach integrating lifestyle interventions and pharmacological strategies can reduce the burden of disease. Seth et al., Herz, 2025
Where GLP-1s fit
The review does not dismiss pharmacotherapy. Its central argument is integrative: lifestyle and medication are now positioned together as new pillars of preventive medicine, and the authors are explicit that only a multifaceted, sustained approach will move long-term outcomes. For readers on or considering GLP-1s, that is the operative phrase. The drugs reduce appetite and body weight in ways that are genuinely new. They do not, on their own, build the muscle that protects glucose handling in later life, restructure a dinner plate, or eliminate the cardiovascular risk that comes with continued smoking.
This is also where the lifestyle conversation becomes especially relevant for people taking these medications. GLP-1 therapy reduces overall food intake, which makes the quality of remaining intake — protein adequacy, fiber, micronutrients — more rather than less important. The Herz review does not address GLP-1 co-management directly, but its insistence on integration is a reasonable lens through which to read the question. This is a conversation to have with a prescribing clinician, not a magazine, but it is the right conversation to have.
- Lifestyle still moves endpoints. A 2025 Herz review reaffirms diet, exercise and smoking cessation as core levers for diabetes, obesity and cardiovascular risk.
- Pattern beats program. Mediterranean and plant-based eating, not branded diets, are what the evidence consistently supports.
- Exercise is a prescription. The review treats physical activity and structured training as serious interventions, not optional add-ons.
- Drugs and lifestyle are complements. The authors frame pharmacotherapy and behavior change as joint pillars, not alternatives.
- Evidence is moderate, not iron-clad. Effect sizes vary across studies; the direction is consistent, the exact magnitude per person is not.
- Talk to a clinician. Especially if you are on or considering a GLP-1, integrate the plan rather than choosing sides.
Resistance training has quietly become a serious cardiometabolic intervention, particularly for adults concerned about preserving muscle during weight loss.
What a careful reader should take away
The most useful posture for a reader of this literature is neither lifestyle purism nor pharmacological maximalism. It is the recognition that the underlying disease processes — inflammation, insulin resistance, neurohormonal activation — are influenced by multiple inputs at once, and that an intervention that addresses one mechanism does not exempt the others.
That is a less satisfying story than a single miracle, and it is also closer to how prevention actually works. The Herz review is, in the end, a corrective rather than a revelation. It reminds clinicians and patients that the boring instruments — what is eaten, how the body is moved, whether cigarettes are still in the picture — were never demoted by the arrival of new drugs. They were joined.